Combination of Interleukin-15 With a STING Agonist, ADU-S100 Analog: A Potential Immunotherapy for Prostate Cancer.
Interleukin-15
NK cells
STING agonist
cytotoxicity
prostate cancer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
26
10
2020
accepted:
12
01
2021
entrez:
29
3
2021
pubmed:
30
3
2021
medline:
30
3
2021
Statut:
epublish
Résumé
Prostate cancer is the second most commonly diagnosed cancer in men with mortality rates, overtaking those for breast cancer in the last 2 years in the UK. Despite advances in prostate cancer treatments, over 25% of men do not survive over 5 years with advanced disease. Due to the success of immunotherapies in treating other cancers, this treatment modality has been investigated for Prostate cancer, however, the sole FDA approved immunotherapy so far (Provenge™) only extends life by a few months. Therefore, finding immunotherapeutic agents to treat prostate cancer is of major interest. Our group has previously shown that Interleukin-15 (IL-15), unlike other therapeutic cytokines such as IL-2 and IL-12, can stimulate expansion and activity of CD8 T cells and NK cells
Identifiants
pubmed: 33777767
doi: 10.3389/fonc.2021.621550
pmc: PMC7988118
doi:
Types de publication
Journal Article
Langues
eng
Pagination
621550Informations de copyright
Copyright © 2021 Esteves, Papaevangelou, Dasgupta and Galustian.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Oncol. 2020 Feb;56(2):439-447
pubmed: 31894265
J Immunol. 2001 Feb 15;166(4):2276-82
pubmed: 11160282
J Biol Chem. 2015 May 8;290(19):12184-94
pubmed: 25792739
Nat Immunol. 2020 Feb;21(2):158-167
pubmed: 31932809
Science. 2010 Jun 25;328(5986):1703-5
pubmed: 20508090
J Clin Invest. 1993 Apr;91(4):1490-8
pubmed: 7682573
Front Immunol. 2017 Mar 31;8:304
pubmed: 28408907
Science. 2013 Feb 15;339(6121):826-30
pubmed: 23258412
Front Immunol. 2015 Jul 20;6:355
pubmed: 26257729
Trends Immunol. 2016 Dec;37(12):855-865
pubmed: 27793569
Cell Rep. 2015 May 19;11(7):1018-30
pubmed: 25959818
Ann Transl Med. 2019 Mar;7(5):105
pubmed: 31019955
Br J Cancer. 2018 Aug;119(4):440-449
pubmed: 30046165
Cell. 2008 May 16;133(4):681-92
pubmed: 18485875
Immunity. 2018 Oct 16;49(4):754-763.e4
pubmed: 30332631
World J Oncol. 2019 Apr;10(2):63-89
pubmed: 31068988
Int Immunol. 2018 Nov 14;30(12):559-567
pubmed: 30085193
Annu Rev Immunol. 2011;29:139-62
pubmed: 21219181
Sci Rep. 2019 Oct 3;9(1):14281
pubmed: 31582793
J Exp Med. 1994 Oct 1;180(4):1395-403
pubmed: 7523571
Cell. 2018 Jun 14;173(7):1770-1782.e14
pubmed: 29906450
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Immunotargets Ther. 2020 Jul 27;9:115-130
pubmed: 32802803
Exp Mol Med. 2020 Apr;52(4):643-657
pubmed: 32284536
J Exp Med. 2004 Apr 5;199(7):925-36
pubmed: 15051762
Immunity. 2015 Feb 17;42(2):332-343
pubmed: 25692705
BJU Int. 2020 Jan;125(1):89-102
pubmed: 31392791
Gene Ther. 2014 Apr;21(4):393-401
pubmed: 24572789
Cancer Treat Rev. 2010 Apr;36(2):131-41
pubmed: 19954892
J Immunother Cancer. 2019 Nov 7;7(1):290
pubmed: 31699153
Cancer Immunol Res. 2017 Jun;5(6):468-479
pubmed: 28483787
Arthritis Res Ther. 2006;8(4):R88
pubmed: 16684368
Blood. 2013 Jun 6;121(23):4672-83
pubmed: 23632890
Mol Cancer. 2019 Nov 4;18(1):152
pubmed: 31679519
Cancer Res. 2020 Apr 15;80(8):1615-1623
pubmed: 32066566
BJU Int. 2016 Oct;118(4):498-500
pubmed: 27367558
Nature. 2009 Oct 8;461(7265):788-92
pubmed: 19776740
Science. 2013 Feb 15;339(6121):786-91
pubmed: 23258413
Oncol Rev. 2016 Apr 15;10(1):293
pubmed: 27471580
Front Immunol. 2018 Feb 02;9:150
pubmed: 29456538
Trends Immunol. 2001 Oct;22(10):556-60
pubmed: 11574279
Cancer Immunol Res. 2015 Apr;3(4):313-9
pubmed: 25847968
Trends Pharmacol Sci. 2012 Jan;33(1):35-41
pubmed: 22032984
Cytokine Growth Factor Rev. 2016 Oct;31:49-59
pubmed: 27325459
Exp Ther Med. 2019 Mar;17(3):2004-2012
pubmed: 30867690
J Clin Immunol. 2002 Mar;22(2):51-6
pubmed: 11998892
Cent Eur J Immunol. 2014;39(1):109-15
pubmed: 26155110
Sci Immunol. 2020 Mar 20;5(45):
pubmed: 32198222
J Immunol. 2007 Jan 1;178(1):85-94
pubmed: 17182543
Nat Commun. 2015 Jan 21;6:6074
pubmed: 25606824
Blood. 2002 Nov 15;100(10):3633-8
pubmed: 12393617
J Immunol. 2017 Jul 15;199(2):397-402
pubmed: 28615418
Cancer Res. 2014 Feb 15;74(4):1056-66
pubmed: 24371227
J Exp Med. 2009 Jan 16;206(1):25-34
pubmed: 19103877
N Engl J Med. 2010 Jul 29;363(5):411-22
pubmed: 20818862
Cell Rep. 2020 Apr 7;31(1):107492
pubmed: 32268090
Stem Cells. 1994 Sep;12(5):456-65
pubmed: 7804122
J Immunol. 2005 Mar 15;174(6):3212-9
pubmed: 15749851
Nat Rev Drug Discov. 2010 Jul;9(7):513-4
pubmed: 20592741
Cell Rep. 2016 Jan 12;14(2):282-97
pubmed: 26748708
Front Immunol. 2018 May 04;9:847
pubmed: 29780381
Nature. 2008 Oct 2;455(7213):674-8
pubmed: 18724357
Mol Cell Biol. 2011 Jul;31(14):2934-46
pubmed: 21576359
Int Immunopharmacol. 2017 Sep;50:121-129
pubmed: 28651122
Nat Rev Immunol. 2006 Dec;6(12):940-52
pubmed: 17124515